They highlighted from this a potential strategy in the development of plasma exosomes, as future cancer biomarkers could be based on functional evaluations of total exosome fractions ex vivo (i.e., using flow-based apoptosis assays after co-incubation of ex vivo EVs with normal immune cell subsets, such as CD8+ Jurkat cells). Here, CD8A is linked to cancer.